Cautionary Note Regarding Forward-Looking Statements
This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s future products and services, or the Company’s plans expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the benefits of the Company’s business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company’s ability to raise financing in the future; the success, cost and timing of the Company’s product development activities; the potential attributes and benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company’s future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services following commercial launch; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
Quantum-Si: The Protein Sequencing Company™

**Experienced Team**
From life sciences leaders including Illumina, Millipore Sigma, PacBio, and Ion Torrent

192 Employees

**Cash runway into 2026**
$322M cash at end of Q1

**Time Domain Sequencing™**
Novel method sequences peptides at the amino acid level in a massively parallel fashion on a semiconductor chip

>1,000 Patents issued & applications pending

**Platinum™**, the world’s first next-generation single-molecule protein sequencing platform is now commercially available

$449K in orders in first quarter of commercial launch

**Peer-Reviewed Technology**
Published in *Science* in October 2022

Proteomics market opportunity valued at $75B+¹

---

Quantum-Si: 1Q23 Financial Highlights

$254K revenue on $449K orders

48.8% Gross Margin

$322M cash at end of 1Q23
Unlocking the Value of the Proteome

Proteins are the main structural and functional components of cells and they are extremely diverse.

- 20,000 Genes (DNA)
  A blueprint of “what could be”

- 200,000 Transcripts (RNA)

- 1,000,000+ Proteoforms (Protein)
  A view of “what is happening”

**Protein modifications** are real-time indicators of health and disease, making them ideal markers for disease, drug response and health.

85% of the human proteome is currently undrugged\(^1\), potential for game changing drug development.

**Next-generation, single-molecule protein sequencing** provides an unbiased view of amino acid mutations and post-translational modifications (PTMs) that can be missed by affinity-based methods.

---

1. Chemical & Engineering News, “A Quest to Drug the Undruggable”, June 20, 2018
Large and Growing Market Opportunity

$75B+ Proteomics Market\(^1\)

$8B+ Initial Target Market\(^2\)

Emerging Clinical $55B+

Research $20B+

Identification $3B+

Expression & Quantification $3B+

Proteoforms & PTM’s $1.5B+

---

2. Decibio Consulting Evaluation, June 2020
The Quantum-Si Solution

Sample Prep
CARBON™ (Launch 2H23)
Universal cartridge based sample preparation and automation

Sequencing & Cloud Analysis
PLATINUM™
Massively Parallel, Single Molecule Detection

Reagents & Chips
CONSUMABLES
Library Prep & Protein Sequencing

Disruptive Technology
Accessible Design
Proven Team & Technology
Quantum-Si’s Technology: Time Domain Sequencing

Massively parallel analysis on a semiconductor chip

Single molecule sequencing reactions in independent wells

Beyond color with Time Domain Sequencing
Proprietary Amino Acid Recognizers Deliver Industry Leading Proteome Coverage

- World class protein engineering and directed evolution program in-house
- Recognition of up to 15 out of 20 amino acids
- Path to >70% coverage of the human proteome
- Identification of up to 90% of proteins, as well as a greater understanding of protein sequence variation and post-translational modifications (PTMs)
- Working to further increase proteome coverage in 2023
Post-Translational Modifications: See What Others Can’t

- **Single-molecule binding kinetics** enables the detection of PTMs without the need to develop new affinity reagents (no *a priori* knowledge is needed)

- ADMA and SDMA have **distinct kinetic signatures** despite having identical mass (these two PTMs are unlikely to be distinguished by mass spec)

- Quantum-Si technology can unlock the ability to study complex disease pathways and discover novel biomarkers
Drug Targets that Modify Proteoforms are Driving M&A Deal Value

• Kinases are drug targets that phosphorylate proteins to generate proteoforms

• $100B in deal value for Kinase inhibitors in the last decade - represents 37% of the total Pharma/Biotech M&A value

• Blockbuster drugs include kinase inhibitors for leukemias (CLL/SLL), melanoma and other cancers

1. BioPharma Dive, “Meet the protein responsible for nearly $100B in cancer drug deals”, August 16, 2019
Accessible to Any Lab, Anywhere

Benchtop instrument; User installable
Low capital cost
Leverages standard laboratory workflow
Simplified and automated data analysis
Quantum-Si Cloud: Automated Data Analysis

Cloud-based analysis software delivers high quality peptide calls that are automated and easy to interpret

**Data from Mass Spectrometry Core Lab**

**Data from the Quantum-Si Cloud**

<table>
<thead>
<tr>
<th>Peptide 1</th>
<th>Probability Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDNF-HUMAN</td>
<td>EPLMFKY</td>
</tr>
<tr>
<td>AT2_HUMAN</td>
<td>FFLCTAPQQBTNEDHLAVK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peptide 2</th>
<th>Probability Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDNF_HUMAN</td>
<td>ENMLCYFGATK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peptide 3</th>
<th>Probability Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDNF_HUMAN</td>
<td>ELISIFCLTVK</td>
</tr>
<tr>
<td>ZN2H7_HUMAN</td>
<td>GLONGAFTTSGSELRIMHDKLRTMPMYCPCGCK</td>
</tr>
<tr>
<td>STRA_HUMAN</td>
<td>DUCHTMODWMNARLBQDVLX</td>
</tr>
<tr>
<td>CDNF_HUMAN</td>
<td>SLORQVNFLQTENK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peptide 4</th>
<th>Probability Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDNF_HUMAN</td>
<td>SLORQVNFLQTENK</td>
</tr>
<tr>
<td>ZN2H7_HUMAN</td>
<td>GLONGAFTTSGSELRIMHDKLRTMPMYCPCGCK</td>
</tr>
<tr>
<td>STRA_HUMAN</td>
<td>DUCHTMODWMNARLBQDVLX</td>
</tr>
<tr>
<td>ZNF7_HUMAN</td>
<td>ELISIFCLTVK</td>
</tr>
<tr>
<td>CDNF_HUMAN</td>
<td>ALQSTRILTRHK</td>
</tr>
</tbody>
</table>

### Table

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Probability Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CDNF-HUMAN</strong></td>
<td>EPLMFKY</td>
</tr>
<tr>
<td><strong>AT2_HUMAN</strong></td>
<td>FFLCTAPQQBTNEDHLAVK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Probability Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CDNF_HUMAN</strong></td>
<td>ENMLCYFGATK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Probability Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CDNF_HUMAN</strong></td>
<td>ELISIFCLTVK</td>
</tr>
<tr>
<td><strong>ZN2H7_HUMAN</strong></td>
<td>GLONGAFTTSGSELRIMHDKLRTMPMYCPCGCK</td>
</tr>
<tr>
<td><strong>STRA_HUMAN</strong></td>
<td>DUCHTMODWMNARLBQDVLX</td>
</tr>
<tr>
<td><strong>CDNF_HUMAN</strong></td>
<td>SLORQVNFLQTENK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Probability Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CDNF_HUMAN</strong></td>
<td>SLORQVNFLQTENK</td>
</tr>
<tr>
<td><strong>ZN2H7_HUMAN</strong></td>
<td>GLONGAFTTSGSELRIMHDKLRTMPMYCPCGCK</td>
</tr>
<tr>
<td><strong>STRA_HUMAN</strong></td>
<td>DUCHTMODWMNARLBQDVLX</td>
</tr>
<tr>
<td><strong>ZNF7_HUMAN</strong></td>
<td>ELISIFCLTVK</td>
</tr>
<tr>
<td><strong>CDNF_HUMAN</strong></td>
<td>ALQSTRILTRHK</td>
</tr>
</tbody>
</table>

### Unique Predictions & Group Predictions

Reference Distribution

![Image of reference distribution]
Quantum-Si is Differentiated from the Competition

<table>
<thead>
<tr>
<th></th>
<th>Quantum-Si</th>
<th>Encodia</th>
<th>Nautilus</th>
<th>SomaLogic</th>
<th>Olink</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercially Available</td>
<td>✔</td>
<td>✗</td>
<td>✗</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Technology</td>
<td>Direct kinetic sequencing</td>
<td>Binding + Degradation with NGS readout</td>
<td>Aptamers/Antibodies</td>
<td>Aptamers</td>
<td>Antibodies</td>
</tr>
<tr>
<td>Instrument Cost</td>
<td>$</td>
<td>$$$*</td>
<td>$$</td>
<td>$$-$$**</td>
<td>$$-$$**</td>
</tr>
<tr>
<td>Run Cost</td>
<td>$</td>
<td>$$-$$**</td>
<td>$$-$$**</td>
<td>$$-$$**</td>
<td>$$-$$**</td>
</tr>
<tr>
<td>AA Sequencing</td>
<td>✔</td>
<td>Limited</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>PTM Detection</td>
<td>✔</td>
<td>?</td>
<td>?</td>
<td>Requires PTM specific reagent development</td>
<td>?</td>
</tr>
<tr>
<td>Automated Data Analysis</td>
<td>✔</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>

Note: *NGS instrument required; **NGS instrument optional
Quantum-Si is Leading the Protein Sequencing Revolution

The analog to digital transition creates new market opportunities – we have seen this before

- Analog: Microarrays
  - DNA Sequencing
    - Affymetrix
    - PacBio
    - ion torrent
- Digital: Protein Sequencing
  - Protein Networks
    - somalogic
    - Olink
    - Quanterix
  - DNA Sequencing
    - illumina
    - SINGULAF
  - Adobe graphic

20,000 Genes (Genomics)
1,000,000+ Proteoforms (Proteomics)
2023 Commercial Priorities

Build a World-Class Team
Expand team across sales, marketing and service in line with achieving key commercial metrics

Drive Awareness Through Data
Posters/presentations at conferences, peer-review publications, webinars

New Product Launches
Launch Carbon, new analysis tools, expanded proteome coverage

Accelerate the Purchase Process
Offer a quick turnaround, proof-of-concept testing service

Industry Partnerships
Deliver the most complete end-to-end suite of products for customers

Develop Product Evangelists
New product testing, publications, peer-to-peer collaboration
Commercial Highlights from 1Q23

**Customer Applications**

- Single Protein ID
- Mixtures
- PTM

**Expanding Awareness**

**Global Sales Funnel**

- US
- EU
Facilitating Adoption via Proof-of-Concept Testing Service

Customer sends samples and pays a modest fee

Quantum-Si sequences samples

Data is analyzed and reported to customer

Customer purchases Platinum
Rapid and Accurate Distinction of Variants of the SARS-CoV-2 Virus

Differentiating Alpha via the L452R mutation

Differentiating Omicron via the K417N mutation
Quantum-Si is off to a Strong Start in 2023

**Commercialize Platinum, Carbon and 2M Chip**
- Platinum launch is on track to internal plan, revenue acceleration in second half;
- Carbon Beta testing is on track to start in 2Q23, launch 2H23

**Lead with Innovation**
- Presented scientific posters at US HUPO, AACR, ABRF; Continuing to develop new data analysis tools and expand proteome coverage;

**Preserve Financial Strength**
- Strong initial gross margins (48.8% in 1Q23); Cash runway into 2026; Continued fiscal discipline